LLY

1,080.48

+0.26%↑

JNJ

231.95

+0.48%↑

ABBV

215.45

+1.3%↑

UNH

381.71

+0.93%↑

AZN

186.94

-0.34%↓

LLY

1,080.48

+0.26%↑

JNJ

231.95

+0.48%↑

ABBV

215.45

+1.3%↑

UNH

381.71

+0.93%↑

AZN

186.94

-0.34%↓

LLY

1,080.48

+0.26%↑

JNJ

231.95

+0.48%↑

ABBV

215.45

+1.3%↑

UNH

381.71

+0.93%↑

AZN

186.94

-0.34%↓

LLY

1,080.48

+0.26%↑

JNJ

231.95

+0.48%↑

ABBV

215.45

+1.3%↑

UNH

381.71

+0.93%↑

AZN

186.94

-0.34%↓

LLY

1,080.48

+0.26%↑

JNJ

231.95

+0.48%↑

ABBV

215.45

+1.3%↑

UNH

381.71

+0.93%↑

AZN

186.94

-0.34%↓

Home・Akciju saraksts・Incyte Corp
Search

Incyte Corp

Atvērts

SektorsVeselības aprūpe

97.56 0.63

Pirkt

Cenas atjauninājums 2026. g. 27. maijs 16:44 UTC

PirktPārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

96.6

Max

98.76

Galvenie mērījumi

By Trading Economics

Ienākumi

4.1M

303M

Pārdošana

-234M

1.3B

P/E

Sektora vidējais

13.723

50.102

EPS

1.81

Peļņas marža

23.834

Darbinieki

2,844

EBITDA

-47M

368M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

+11.46% upside

Dividendes

By Dow Jones

Nākamie ieņēmumi

2026. g. 28. jūl.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

362M

19B

Iepriekšējā atvēršanas cena

96.93

Iepriekšējā slēgšanas cena

97.56

Ziņu noskaņojums

By Acuity

55%

45%

275 / 344 Rangs Healthcare

Incyte Corp Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 26. maijs 16:52 UTC

Galvenie ziņu notikumi

NYMEX Overview: Brent Crude Futures Up; Iran Warns of Retaliation After US Strike -- OPIS

DJ

Lasīt

2026. g. 26. maijs 23:57 UTC

Peļņas

Sociedad Quimica 1Q Rev $1.76B >SQM

DJ

Lasīt

2026. g. 26. maijs 23:57 UTC

Peļņas

Sociedad Quimica 1Q EPS $1.28 >SQM

DJ

Lasīt

2026. g. 26. maijs 23:48 UTC

Tirgus saruna

Nikkei May Rise on Continued AI Enthusiasm -- Market Talk

DJ

Lasīt

2026. g. 26. maijs 21:54 UTC

Peļņas

Webco Industries 3Q EPS $11.61 >WEBC

DJ

Lasīt

2026. g. 26. maijs 21:54 UTC

Peļņas

Webco Industries 3Q Sales $179.6M >WEBC

DJ

Lasīt

2026. g. 26. maijs 21:48 UTC

Tirgus saruna

GE Aerospace's Repair Boom Should Last for Years -- Market Talk

DJ

Lasīt

2026. g. 26. maijs 21:00 UTC

Tirgus saruna

ESG Roundup: Market Talk

DJ

Lasīt

2026. g. 26. maijs 20:58 UTC

Iegādes, apvienošanās, pārņemšana

Uber's $11.6 Billion Bid for DoorDash Rival Is About Future Proofing It From Robots -- Barrons.com

DJ

Lasīt

2026. g. 26. maijs 20:50 UTC

Tirgus saruna

Tech, Media & Telecom Roundup: Market Talk

DJ

Lasīt

2026. g. 26. maijs 20:50 UTC

Tirgus saruna

Auto & Transport Roundup: Market Talk

DJ

Lasīt

2026. g. 26. maijs 20:50 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

DJ

Lasīt

2026. g. 26. maijs 19:22 UTC

Tirgus saruna

Cryptocurrencies Add to Losses in Afternoon Trading -- Market Talk

DJ

Lasīt

2026. g. 26. maijs 19:17 UTC

Tirgus saruna

Oil Recovers Some Losses on U.S.-Iran Skirmishes -- Market Talk

DJ

Lasīt

2026. g. 26. maijs 18:56 UTC

Tirgus saruna

U.S. Natural Gas Futures Slip in Rangebound Trading -- Market Talk

DJ

Lasīt

2026. g. 26. maijs 18:03 UTC

Tirgus saruna

AutoCanada Faces Soft Demand, Slow Normalization -- Market Talk

DJ

Lasīt

2026. g. 26. maijs 17:42 UTC

Tirgus saruna

Grains Await Fresh Trading Catalyst -- Market Talk

DJ

Lasīt

2026. g. 26. maijs 17:33 UTC

Tirgus saruna

Salesforce, Snowflake Could Dispel Software Bear Thesis -- Market Talk

DJ

Lasīt

2026. g. 26. maijs 17:21 UTC

Tirgus saruna

Canada Faces a Labor Market Squeeze -- Market Talk

DJ

Lasīt

2026. g. 26. maijs 16:52 UTC

Tirgus saruna

Bonds to Fund Infrastructure for Data Centers Could Be Risky -- Market Talk

DJ

Lasīt

2026. g. 26. maijs 16:43 UTC

Tirgus saruna

Spotify's Latest Audio Play: Magazine Articles -- Market Talk

DJ

Lasīt

2026. g. 26. maijs 16:24 UTC

Tirgus saruna

Dollarama's LATAM Slowdown, Australia Costs Seen as Transient -- Market Talk

DJ

Lasīt

2026. g. 26. maijs 16:21 UTC

Tirgus saruna

Oil Extends Gains As Strikes Add Tension to U.S.-Iran Talks -- Market Talk

DJ

Lasīt

2026. g. 26. maijs 16:20 UTC

Tirgus saruna

Tech, Media & Telecom Roundup: Market Talk

DJ

Lasīt

2026. g. 26. maijs 16:20 UTC

Tirgus saruna

Energy & Utilities Roundup: Market Talk

DJ

Lasīt

2026. g. 26. maijs 16:20 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

DJ

Lasīt

2026. g. 26. maijs 16:20 UTC

Tirgus saruna
Iegādes, apvienošanās, pārņemšana

Auto & Transport Roundup: Market Talk

DJ

Lasīt

2026. g. 26. maijs 16:16 UTC

Tirgus saruna

Alberta Separation Threat Poses Headwind for Canada Dollar -- Market Talk

DJ

Lasīt

2026. g. 26. maijs 16:01 UTC

Tirgus saruna

Bitcoin Lower as Stress Builds for Holders -- Market Talk

DJ

Lasīt

2026. g. 26. maijs 15:21 UTC

Tirgus saruna

Hyperliquid Pushes Up to New All-Time High -- Market Talk

DJ

Lasīt

Salīdzinājums

Cenas izmaiņa

Incyte Corp Prognoze

Cenas mērķis

By TipRanks

11.46% augšup

Prognoze 12 mēnešiem

Vidējais 108.29 USD  11.46%

Augstākais 135 USD

Zemākais 75 USD

Pamatojoties uz 19 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Incyte Corp — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

19 ratings

8

Pirkt

10

Turēt

1

Pārdot

Pamatojoties uz 19 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Incyte Corp — pēdējo 3 mēnešu laikā.

Noskaņojums

By Acuity

275 / 344 Rangs Veselības aprūpe

Ziņu noskaņojums

Liecība "Lāču" tendencei

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Virs vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Incyte Corp

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation

Citi krājumi no sektora

LLY

Eli Lilly and Co.

1,080.48

↑ +0.26%

JNJ

Johnson and Johnson

231.95

↑ +0.48%

ABBV

AbbVie Inc

215.45

↑ +1.3%

UNH

UnitedHealth Group Inc

381.71

↑ +0.93%

AZN

AstraZeneca PLC

186.94

↓-0.34%
help-icon Live chat